Logo image of AMPH

AMPHASTAR PHARMACEUTICALS IN (AMPH) Stock Fundamental Analysis

USA - NASDAQ:AMPH - US03209R1032 - Common Stock

27.42 USD
+0.44 (+1.63%)
Last: 9/18/2025, 3:38:02 PM
Fundamental Rating

6

AMPH gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. AMPH has an excellent profitability rating, but there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on AMPH. These ratings could make AMPH a good candidate for value investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year AMPH was profitable.
In the past year AMPH had a positive cash flow from operations.
In the past 5 years AMPH has always been profitable.
In the past 5 years AMPH always reported a positive cash flow from operatings.
AMPH Yearly Net Income VS EBIT VS OCF VS FCFAMPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

1.2 Ratios

Looking at the Return On Assets, with a value of 8.34%, AMPH belongs to the top of the industry, outperforming 91.84% of the companies in the same industry.
AMPH has a Return On Equity of 17.78%. This is amongst the best in the industry. AMPH outperforms 90.82% of its industry peers.
AMPH has a Return On Invested Capital of 10.47%. This is amongst the best in the industry. AMPH outperforms 87.24% of its industry peers.
The Average Return On Invested Capital over the past 3 years for AMPH is below the industry average of 15.28%.
Industry RankSector Rank
ROA 8.34%
ROE 17.78%
ROIC 10.47%
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
AMPH Yearly ROA, ROE, ROICAMPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 10 15 20

1.3 Margins

Looking at the Profit Margin, with a value of 18.64%, AMPH belongs to the top of the industry, outperforming 91.84% of the companies in the same industry.
AMPH's Profit Margin has improved in the last couple of years.
AMPH has a better Operating Margin (25.14%) than 91.33% of its industry peers.
In the last couple of years the Operating Margin of AMPH has grown nicely.
Looking at the Gross Margin, with a value of 49.86%, AMPH is in the better half of the industry, outperforming 62.76% of the companies in the same industry.
AMPH's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 25.14%
PM (TTM) 18.64%
GM 49.86%
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
AMPH Yearly Profit, Operating, Gross MarginsAMPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40 50

More info and screens

6

2. Health

2.1 Basic Checks

AMPH has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
AMPH has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, AMPH has more shares outstanding
AMPH has a better debt/assets ratio than last year.
AMPH Yearly Shares OutstandingAMPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AMPH Yearly Total Debt VS Total AssetsAMPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 2.54 indicates that AMPH is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.54, AMPH is in the better half of the industry, outperforming 69.90% of the companies in the same industry.
AMPH has a debt to FCF ratio of 5.54. This is a neutral value as AMPH would need 5.54 years to pay back of all of its debts.
AMPH's Debt to FCF ratio of 5.54 is amongst the best of the industry. AMPH outperforms 81.63% of its industry peers.
A Debt/Equity ratio of 0.80 indicates that AMPH is somewhat dependend on debt financing.
AMPH's Debt to Equity ratio of 0.80 is on the low side compared to the rest of the industry. AMPH is outperformed by 69.90% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.8
Debt/FCF 5.54
Altman-Z 2.54
ROIC/WACC1.12
WACC9.38%
AMPH Yearly LT Debt VS Equity VS FCFAMPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 3.29 indicates that AMPH has no problem at all paying its short term obligations.
AMPH's Current ratio of 3.29 is in line compared to the rest of the industry. AMPH outperforms 58.67% of its industry peers.
AMPH has a Quick Ratio of 2.21. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
AMPH's Quick ratio of 2.21 is in line compared to the rest of the industry. AMPH outperforms 46.94% of its industry peers.
Industry RankSector Rank
Current Ratio 3.29
Quick Ratio 2.21
AMPH Yearly Current Assets VS Current LiabilitesAMPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for AMPH have decreased strongly by -13.47% in the last year.
The Earnings Per Share has been growing by 61.62% on average over the past years. This is a very strong growth
Looking at the last year, AMPH shows a small growth in Revenue. The Revenue has grown by 1.37% in the last year.
Measured over the past years, AMPH shows a quite strong growth in Revenue. The Revenue has been growing by 17.82% on average per year.
EPS 1Y (TTM)-13.47%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-9.57%
Revenue 1Y (TTM)1.37%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%-4.38%

3.2 Future

The Earnings Per Share is expected to grow by 0.50% on average over the next years.
AMPH is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.23% yearly.
EPS Next Y-11.62%
EPS Next 2Y-0.07%
EPS Next 3Y2.83%
EPS Next 5Y0.5%
Revenue Next Year-0.8%
Revenue Next 2Y2.99%
Revenue Next 3Y3.52%
Revenue Next 5Y4.23%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AMPH Yearly Revenue VS EstimatesAMPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
AMPH Yearly EPS VS EstimatesAMPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 2 3 4

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 7.90, which indicates a rather cheap valuation of AMPH.
Based on the Price/Earnings ratio, AMPH is valued cheaply inside the industry as 92.35% of the companies are valued more expensively.
AMPH is valuated cheaply when we compare the Price/Earnings ratio to 27.20, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 7.11 indicates a rather cheap valuation of AMPH.
Based on the Price/Forward Earnings ratio, AMPH is valued cheaply inside the industry as 92.86% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of AMPH to the average of the S&P500 Index (22.70), we can say AMPH is valued rather cheaply.
Industry RankSector Rank
PE 7.9
Fwd PE 7.11
AMPH Price Earnings VS Forward Price EarningsAMPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

94.90% of the companies in the same industry are more expensive than AMPH, based on the Enterprise Value to EBITDA ratio.
AMPH's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AMPH is cheaper than 89.80% of the companies in the same industry.
Industry RankSector Rank
P/FCF 11.6
EV/EBITDA 6.55
AMPH Per share dataAMPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

AMPH has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.13
EPS Next 2Y-0.07%
EPS Next 3Y2.83%

More info and screens

0

5. Dividend

5.1 Amount

AMPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMPHASTAR PHARMACEUTICALS IN

NASDAQ:AMPH (9/18/2025, 3:38:02 PM)

27.42

+0.44 (+1.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners72.89%
Inst Owner Change-2.86%
Ins Owners9.16%
Ins Owner Change2.88%
Market Cap1.28B
Analysts78.33
Price Target33.86 (23.49%)
Short Float %11.76%
Short Ratio7.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.06%
Min EPS beat(2)5.65%
Max EPS beat(2)12.46%
EPS beat(4)2
Avg EPS beat(4)2.21%
Min EPS beat(4)-4.74%
Max EPS beat(4)12.46%
EPS beat(8)5
Avg EPS beat(8)11.25%
EPS beat(12)8
Avg EPS beat(12)16.86%
EPS beat(16)12
Avg EPS beat(16)21.21%
Revenue beat(2)0
Avg Revenue beat(2)-1.89%
Min Revenue beat(2)-2.43%
Max Revenue beat(2)-1.36%
Revenue beat(4)0
Avg Revenue beat(4)-2.59%
Min Revenue beat(4)-3.71%
Max Revenue beat(4)-1.36%
Revenue beat(8)2
Avg Revenue beat(8)-1.01%
Revenue beat(12)5
Avg Revenue beat(12)-0.37%
Revenue beat(16)9
Avg Revenue beat(16)0.92%
PT rev (1m)1.37%
PT rev (3m)0.61%
EPS NQ rev (1m)-2.35%
EPS NQ rev (3m)4.47%
EPS NY rev (1m)6.38%
EPS NY rev (3m)6.07%
Revenue NQ rev (1m)0.27%
Revenue NQ rev (3m)0.73%
Revenue NY rev (1m)0.44%
Revenue NY rev (3m)0.69%
Valuation
Industry RankSector Rank
PE 7.9
Fwd PE 7.11
P/S 1.76
P/FCF 11.6
P/OCF 7.99
P/B 1.68
P/tB 7.12
EV/EBITDA 6.55
EPS(TTM)3.47
EY12.65%
EPS(NY)3.85
Fwd EY14.06%
FCF(TTM)2.36
FCFY8.62%
OCF(TTM)3.43
OCFY12.52%
SpS15.54
BVpS16.29
TBVpS3.85
PEG (NY)N/A
PEG (5Y)0.13
Profitability
Industry RankSector Rank
ROA 8.34%
ROE 17.78%
ROCE 12.63%
ROIC 10.47%
ROICexc 12.47%
ROICexgc 23.95%
OM 25.14%
PM (TTM) 18.64%
GM 49.86%
FCFM 15.21%
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
ROICexc(3y)16.46%
ROICexc(5y)13%
ROICexgc(3y)29.66%
ROICexgc(5y)21.24%
ROCE(3y)15.59%
ROCE(5y)12.24%
ROICexcg growth 3Y24.9%
ROICexcg growth 5YN/A
ROICexc growth 3Y2.33%
ROICexc growth 5YN/A
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
F-Score5
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.8
Debt/FCF 5.54
Debt/EBITDA 2.51
Cap/Depr 82.12%
Cap/Sales 6.88%
Interest Coverage 7.38
Cash Conversion 65.92%
Profit Quality 81.61%
Current Ratio 3.29
Quick Ratio 2.21
Altman-Z 2.54
F-Score5
WACC9.38%
ROIC/WACC1.12
Cap/Depr(3y)86.1%
Cap/Depr(5y)106.5%
Cap/Sales(3y)5.45%
Cap/Sales(5y)6.46%
Profit Quality(3y)95%
Profit Quality(5y)414.14%
High Growth Momentum
Growth
EPS 1Y (TTM)-13.47%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-9.57%
EPS Next Y-11.62%
EPS Next 2Y-0.07%
EPS Next 3Y2.83%
EPS Next 5Y0.5%
Revenue 1Y (TTM)1.37%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%-4.38%
Revenue Next Year-0.8%
Revenue Next 2Y2.99%
Revenue Next 3Y3.52%
Revenue Next 5Y4.23%
EBIT growth 1Y-20.98%
EBIT growth 3Y43.24%
EBIT growth 5YN/A
EBIT Next Year-3.45%
EBIT Next 3Y2.76%
EBIT Next 5Y5.95%
FCF growth 1Y9.39%
FCF growth 3Y34.69%
FCF growth 5Y286.43%
OCF growth 1Y21.97%
OCF growth 3Y29.62%
OCF growth 5Y38.57%